- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02956772
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and accounts for significant morbidity and mortality worldwide. Notably, more than half of the new HCC cases and deaths develop in China. Transarterial chemoembolization (TACE) has been proposed as the first-line therapeutic strategy for the treatment of patients with unresectable HCC. However, TACE has several limitations itself which might be potentially associated with tumor metastasis and relapse.
Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several small studies in China showed promising clinical benefits when As2O3 is administrated among the HCC patients. With these preliminary results, the investigators are planning to carry out a multicenter randomized controlled trial through which to explore the potential efficacy and safety of adjuvant As2O3 treatment for HCC patients.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Lin Long, Dr.
- Numero di telefono: 86-13507476175
Backup dei contatti dello studio
- Nome: Hua Xiang, Dr.
- Numero di telefono: 85-13667367061
Luoghi di studio
-
-
Guizhou
-
Guiyang, Guizhou, Cina
- Guizhou Cancer Hospital
-
Contatto:
- Shi Zhou, Dr.
- Email: 258600801@qq.com
-
Guiyang, Guizhou, Cina
- Guizhou Province Tumor Hospital
-
Contatto:
- Junxiang Li, Dr.
- Email: 258600801@qq.com
-
-
Hunan
-
Changsha, Hunan, Cina
- Hunan Cancer Hospital
-
Contatto:
- Guowen LI, Dr.
- Email: liguowen@hnszlyy.com
-
Changsha, Hunan, Cina
- Xiangya Hospital Central South University
-
Contatto:
- Chunhui Zhou, Dr.
- Email: zhouchunhui2016@163.com
-
Changsha, Hunan, Cina, 410001
- Hunan Provincial People's Hospital
-
Contatto:
- Hua Xiang, Dr.
- Numero di telefono: +86-13667367061
-
Contatto:
- Lin Long, Dr.
- Numero di telefono: +86-13507476175
- Email: doclongll@163.com
-
Hengyang, Hunan, Cina
- The First Affiliated Hospital of University of South China
-
Contatto:
- Youhua Wu, Dr.
- Email: 330270372@qq.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina
- Jiangsu Province Hospital
-
Contatto:
- Zhen-Qiang Yang, Dr.
- Email: ntdoctoryang@hotmail.com
-
-
Xinjiang
-
Urumqi, Xinjiang, Cina
- Xinjiang Medical University Cancer Hospital
-
Contatto:
- Shufa Yang, Dr.
- Email: yangshufa2013@sina.com
-
-
Yunnan
-
Kunming, Yunnan, Cina
- The Tumor Hospital of Yunnan Province
-
Contatto:
- Ming Huang, Dr.
- Email: huangming4328@sina.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- Subject is 18-80 years old.
- Subject has no portal stem vein tumor thrombus.
- Subject has primary middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C inappropriate for surgical resection or other locoregional therapy and still presents with tumor lesions in the liver.
- Subject has evaluable tumor lesion(s) (using Magnetic Resonance Imaging /Computed Tomography) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1: single lesion size ≥5cm or at least one lesion of >3cm in size when 2-3 lesions exist or there are 4 or more lesions.
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤1, Fibrosis index based on 4 factors (FIB-4)≤6 and an expected survival time of 12 weeks or more.
- Haematology: white blood cell count ≥3.0×10^9/L; hemoglobin≥10 g/dL; blood platelet count≥80×10^9/L
- Blood biochemistry: serum albumin ≥2.8 g/dL, total bilirubin ≤2 mg/dL or ≤34.2 umol/L, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 times of upper limit of normal (ULN); amylase and lipase ≤ 1.5 times of ULN; serum creatinine ≤2.0 mg/dL or < 1.5 times of ULN; estimated creatinine clearance ≥60 mL/min.
- International normalized ratio (INR) is ≤ 2.3 or prothrombin time (PT) is ≤3 seconds than upper limit of normal control.
- Echocardiogram indicated a left ventricular ejection fraction (LVEF) of >50%.
- Subject has a liver function Child-Pugh class A or B.
- Subject is not pregnant or lactating.
- Female subjects must be infertile or agree to take effective contraceptives; male subjects and their partners of reproductive potential must also agree to use appropriate contraceptives.
- Subject had no second tumor in the last 5 years, excluding skin basal cell carcinoma or skin squamous carcinoma or any other carcinoma in situ.
- Subject had no history of systemic chemotherapy.
- Subject has no any other concomitant anticancer therapies, such as local radiotherapy, systemic chemotherapy and molecular targeted therapy.
- Subject and (or) guardian is able to understand this study and willing to provide written, informed consent to participate in this clinical study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: TACE plus Arsenic Trioxide
Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21).
TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks.
At least 3 cycles of arsenic trioxide are administrated.
|
After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed.
Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid.
Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
|
Comparatore attivo: TACE
Patients in this group are to receive a single dose of TACE treatment on day 1.
TACE treatment is repeated every 9 weeks for 27 weeks.
|
After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed.
Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid.
Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Progression free survival
Lasso di tempo: 2-year
|
Progression free survival (PFS) is defined as the time interval from the day of the random assignment to the first evidence of progression or death.
|
2-year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Objective response rate
Lasso di tempo: 2-year
|
Tumor response is defined as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to RECIST and will be assessed by the investigators.
The tumor objective response rate (ORR) is calculated per treatment arm as the proportion of randomized patients having a confirmed best response of CR or PR.
|
2-year
|
Overall Survival
Lasso di tempo: 2-year
|
Overall survival will be measured from the date of randomization up to the date of death of any cause
|
2-year
|
Incidence of adverse events
Lasso di tempo: Up to 2 years through study completion
|
Toxicities will be evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v 4.0.
|
Up to 2 years through study completion
|
Altre misure di risultato
Misura del risultato |
Lasso di tempo |
---|---|
Quality of life using EuroQol five dimensions five levels questionnaire
Lasso di tempo: Baseline and week 6, 12, 18, 24 and 30 using EuroQol five dimensions five levels questionnaire
|
Baseline and week 6, 12, 18, 24 and 30 using EuroQol five dimensions five levels questionnaire
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Hua Xiang, Dr., Hunan Provincial People's Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RACE16001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su TACE
-
Beijing Tsinghua Chang Gung HospitalSconosciutoCarcinoma epatocellulare (HCC) con trombosi tumorale della vena porta di tipo III (PVTT)Cina
-
Beijing Tsinghua Chang Gung HospitalSconosciutoEnorme carcinoma epatocellulare (HCC) (≥10 cm)Cina
-
Shanghai Zhongshan HospitalReclutamentoCarcinoma epatocellulare | DonafenibCina
-
Sun Yat-sen UniversitySconosciutoCarcinoma epatocellulare | Cancro al fegatoCina
-
Sun Yat-sen UniversitySconosciutoCarcinoma epatocellulare | Cancro al fegatoCina
-
Kindai UniversitySconosciutoCarcinoma, epatocellulare | Carcinoma epatocellulare | Neoplasia epatica | Carcinoma epatocellulare non resecabileGiappone
-
Ivy Life Sciences, Co., LtdTri-Service General HospitalSconosciutoCancro al fegato | Carcinoma epatocellulareTaiwan
-
Fudan UniversitySconosciuto
-
Ain Shams UniversityCompletato
-
Zhongda HospitalReclutamento